IE
LGND icon

Israel Englander’s Ligand Pharmaceuticals LGND Stock Holding History

Israel Englander’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-71,494
Closed -$9.24M – 4112
2018
Q2 		$9.24M Buy
+71,494
New +$7.98M 0.01% 1371

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's LGND Position: Q2 2026 in Review

Israel Englander opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 3,975 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #4171 among its holdings. This is a return to the name: Israel Englander previously reported a position in LGND as recently as Q1 2025.

Israel Englander first reported a position in LGND in Q2 2013 and has held it in 36 quarters since. The position peaked at $74.2M in Q4 2018. 413 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Israel Englander held 3,975 shares of Ligand Pharmaceuticals worth $1.26M as of Q2 2026.
  • Ligand Pharmaceuticals was a new Israel Englander position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4171 holding.
  • Israel Englander first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
  • Israel Englander's Ligand Pharmaceuticals position peaked at $74.2M in Q4 2018.
  • 413 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.